The horizon of antiangiogenic therapy for colorectal cancer

ONCOLOGY

Volumn 19, Issue 3, 2005, Pages 297-306

  Olszewski, Adam J ^a   Grossbard, Michael L ^a,b   Kozuch, Peter S ^a,b  

^a ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^b Beth Israel Medical Center ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5,6,7,13 TETRAHYDRO 12 (3 HYDROXYPROPYL) 9 ISOPROPOXYMETHYLINDENO[2,1 A]PYRROLO[3,4 C]CARBAZOL 5(12H) ONE DIMETHYLGLYCINE ESTER; AE 941; BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; SEMAXANIB; VANDETANIB; VASCULOTROPIN; VATALANIB; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; VASCULOTROPIN A;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ASTHENIA; BLEEDING; BLOOD PRESSURE FLUCTUATION; BRAIN HEMORRHAGE; CANCER ADJUVANT THERAPY; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG HALF LIFE; DRUG INHIBITION; DRUG SAFETY; DRUG TOLERABILITY; FEVER; HEADACHE; HUMAN; HYPERTENSION; LUNG EMBOLISM; METASTASIS; MULTIPLE CYCLE TREATMENT; PNEUMONIA; PROTEINURIA; RASH; REVIEW; SIDE EFFECT; COLORECTAL TUMOR; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG ANTAGONISM; NEOVASCULARIZATION (PATHOLOGY);

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 21244452269     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (66)

1. Leenders WPJ: Targetting VEGF in anti-angiogenic and anti-tumour therapy: Where are we now? Int J Exp Pathol 79:339-346, 1998.
2. Connolly DT, Heuvelman DM, Nelson R, et al: Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J Clin Invest 84:1470-1478, 1989.
3. Ferrara N, Davis-Smyth T: The biology of vascular endothelial growth factor. Endocrine Rev 18:4-25, 1997.
4. Jakeman LB, Winer J, Bennett GL, et al: Binding sites for vascular endothelial growth factor are localized on endothelial cells in adult rat tissues. J Clin Invest 89:244-253, 1992.
5. Waltenberger J, Claesson-Welsh L, Siegbahn A, et al: Different signal transduction properties of KDR and FIt1, two receptors for vascular endothelial growth factor. J Biol Chem 269:26988-26995, 1994.
6. Folkman J: What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82:4-6, 1990.
7. Brown LF, Berse B, Jackman RW, et al: Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res 53:4727-4735, 1993.
8. Kumar H, Heer K, Lee PW, et al: Preoperative serum vascular endothelial growth factor can predict stage in colorectal cancer. Clin Cancer Res 4:1279-1285, 1998.
9. Werther K, Christensen IJ, Brunner N, et al: Soluble vascular endothelial growth factor levels in patients with primary colorectal carcinoma. Eur J Surg Oncol 26:657-662, 2000.
10. Ishigami SI, Arii S, Furutani M, et al: Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer. Br J Cancer 78:1379-1384, 1998.
11. Cascinu S, Staccioli MP, Gasparini G, et al: Expression of vascular endothelial growth factor can predict event-free survival in stage II colon cancer. Clin Cancer Res 6:2803-2807, 2000.
12. Chin KF, Greenman J, Kumar H, et al: Pre-operative serum vascular endothelial growth factor can select patients for adjuvant treatment after curative resection in colorectal cancer. Br J Cancer 83:1425-1431, 2000.
13. Kim KJ, Li B, Winer J, et al: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362:841-844, 1993.
14. Warren RS, Yuan H, Matli MR, et al: Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest 95:1789-1797, 1995.
15. Gordon MS, Margolin K, Talpaz M, et al: Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 19:843-850, 2001.
16. Gaudreault J, Bruno R, Kabbinavar F, et al: Clinical pharmacokinetics of bevacizumab following every 2- or every 3-week dosing (abstract 3041). Proc Am Soc Clin Oncol 23:205, 2004.
17. Margolin K, Gordon MS, Holmgren E, et al: Phase Ib trial of recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: Pharmacologic and long-term safety data. J Clin Oncol 19:851-856, 2001.
18. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al: Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21:60-65, 2003.
19. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004.
20. Novotny WF, Holmgren E, Nelson B, et al: Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) does not increase the incidence of venous thromboembolism when added to first-line chemotherapy to treat metastatic colorectal cancer (abstract 3529). Proc Am Soc Clin Oncol 23:252, 2004.
21. Hambleton J, Novotny WF, Hurwitz H, et al: Bevacizumab does not increase bleeding in patients with metastatic colorectal cancer receiving concurrent anticoagulation (abstract 3528). Proc Am Soc Clin Oncol 23:252, 2004.
22. Giantonio BJ, Levy D, O'Dwyer PJ, et al: Bevacizumab (anti-VEGF) plus IFL (irinotecan, fluorouracil, leucovorin) as frontline therapy for advanced colorectal cancer (advCRC): Updated results from the Eastern Cooperative Oncology Group (ECOG) Study E2200 (abstract 289). Program and abstracts of the Gastrointestinal Cancers Symposium, San Francisco, January 22, 2004.
23. DeVore R, Fehrenbacher L, Herbst R, et al: A randomized phase II trial comparing rhumab VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus carboplatin/paclitaxel (CP) to CP alone in patients with stage IIIB/IV NSCLC (abstract 1896). Proc Am Soc Clin Oncol 19: 2000.
24. Goldberg RM, Sargent DJ, Morton RF, et al: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23-30, 2004.
25. Kabbinavar FF, Schulz J, McCleod M, et al: Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) to prolong progression-free survival in first-line colorectal cancer (CRC) in subjects who are not suitable candidates for first-line CPT-11 (abstract 3516). Proc Am Soc Clin Oncol 23:249, 2004.
26. Goldberg RM, Sargent DJ, Morton RF, et al: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23-30, 2004.
27. Douillard JY, Cunningham D, Roth AD, et al: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 355:1041-1047, 2000.
28. Hedrick EE, Hurwitz H, Sarkar S, et al: Post-progression therapy (PPT) effect on survival in AVF2107, a phase III trial of bevacizumab in first-line treatment of metastatic colorectal cancer (mCRC) (abstract 3517). Proc Am Soc Clin Oncol 23:249, 2004.
29. Giantonio BJ, Catalano PJ, Meropol NJ, et al: High-dose bevacizumab in combination with FOLFOX-4 improves survival in patients with previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200 (abstract 169a). Program and abstracts of the Gastrointestinal Cancers Symposium, Hollywood, FIa, January 27, 2005.
30. Maughan TS, James RD, Kerr DJ, et al: Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: A multicentre randomised trial. Lancet 361:457-464, 2003.
31. Scappaticci F, Fehrenbacher L, Cartwright T, et al: Lack of effect of bevacizumab on wound healing/bleeding complications when given 28-60 days following primary cancer surgery (abstract 3530). Proc Am Soc Clin Oncol 23:253, 2004.
32. Andre T, Boni C, Mounedji-Boudiaf L: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350:2343-2351, 2004.
33. Chau I, Chan S, Cunningham D: Overview of preoperative and postoperative therapy for colorectal cancer: The European and United States perspectives. Clin Colorectal Cancer 3:19-33, 2003.
34. Gorski DH, Beckett MA, Jaskowiak NT, et al: Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 59:3374-3378, 1999.
35. Willett CG, Boucher Y, Di Tomaso E, et al: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10:145-147, 2004.
36. Wildiers H, Guetens G, De Boeck G, et al: Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. Br J Cancer 88:1979-1986, 2003.
37. Pietras K, Rubin K, Sjoblom T, et al: Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res 62:5476-5484, 2002.
38. Jain RK: The next frontier of molecular medicine: Delivery of therapeutics. Nat Med 4:655-657, 1998.
39. Netti PA, Hamberg LM, Babich JW, et al: Enhancement of fluid filtration across tumor vessels: Implication for delivery of macromolecules. Proc Natl Acad Sci U S A 96:3137-3142, 1999.
40. Lee CG, Heijn M, di Tomaso E, et al: Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 60:5565-5570, 2000.
41. Kindler HL, Friberg G, Stadler WM, et al: Bevacizumab plus gemcitabine is an active combination in patients with advanced pancreatic cancer: Interim results of an ongoing phase II trial from the University of Chicago Phase II Consortium (abstract 86). Program and abstracts of the Gastrointestinal Cancers Symposium, San Francisco, January 22, 2004.
42. Sugimoto H, Hamano Y, Charytan D, et al: Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem 278:12605-12608, 2003.
43. Annie T, Fong T, Shawver LK, et al: SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 59:99-106, 1999.
44. Miller LL, Elfring GL, Hannah AL, et al: Efficacy results of a phase I/II study of SU5416 (S)/5-fIuorouracil (F)/leucovorin (L) relative to results in random subsets of similar patients (Pts) from a phase III study of irinotecan (C)/F/L or F/L alone in the therapy of previously untreated metastatic colorectal cancer (MCRC) (abstract 571). Proc Am Soc Clin Oncol 20:144a, 2001.
45. Saltz LB, Cox JV, Blanke C, et al: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 343:905-914, 2000.
46. Venook A, Hurwitz H, Cunningham C, et al: Relationship of clinical outcome in metastatic colorectal carcinoma to levels of soluble VEGFR-1: Results of a phase II trial of a ribozyme targeting the pre-mRNA of VEGFR-1 (angiozyme), in combination with chemotherapy (abstract 1025). Proc Am Soc Clin Oncol 22:256, 2003.
47. Wedge SR, Ogilvie DJ, Dukes M, et al: ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 62:4645-4655, 2002.
48. Minami H, Ebi H, Tahara M, et al: A phase I study of an oral VEGF receptor tyrosine kinase inhibitor ZD6474, in Japanese patients with solid tumors (abstract 778). Proc Am Soc Clin Oncol 22:194, 2003.
49. Hurwitz H, Holden SN, Eckhardt SG, et al: Clinical evaluation of ZD6474, an orally active inhibitor of VEGF signaling, in patients with solid tumors (abstract 325). Proc Am Soc Clin Oncol 21:82a, 2002.
50. Wood JM, Bold G, Buchdunger E, et al: PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 60:2178-2189, 2000.
51. Steward WP, Thomas A, Morgan B, et al: Expanded phase I/II study of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in combination with FOLFOX-4 as first-line treatment for patients with metastatic colorectal cancer (abstract 3556). Proc Am Soc Clin Oncol 23:259, 2004.
52. Morgan B, Thomas AL, Drevs J, et al: Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: Results from two phase I studies. J Clin Oncol 21:3955-3964, 2003.
53. Ruggeri B, Singh J, Gingrich D, et al: CEP-7055: A novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models. Cancer Res 63:5978-5991, 2003.
54. Beliveau R, Gingras D, Kruger EA, et al: The antiangiogenic agent neovastat (AE-941) inhibits vascular endothelial growth factor-mediated biological effects. Clin Cancer Res 8:1242-1250, 2002.
55. Latreille J, Batist G, Laberge F, et al: Phase I/II trial of the safety and efficacy of AE-941 (Neovastat) in the treatment of non-small-cell lung cancer. Clin Lung Cancer 4:231-236, 2003.
56. Lu C, Komaki R, Herbst RS, et al: A phase III study of AE-941 with induction chemotherapy (IC) and concomitant chemoradiotherapy (CRT) for stage III non-small cell lung cancer (NSCLC) (NCI T99-0046, RTOG 02-70, MDA 99-303): An interim overall toxicity report (abstract 2665). Proc Am Soc Clin Oncol 22:663, 2003.
57. Holash J, Davis S, Papadopoulos N, et al: VEGF-Trap: A VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A 99:11393-11398, 2002.
58. Huang J, Frischer JS, Serur A, et al: Regression of established tumors and metastases by potent vascular endothelial growth factor blockade. Proc Natl Acad Sci USA 100:7785-7790, 2003.
59. Kim ES, Serur A, Huang J, et al: Potent VEGF blockade causes regression of co-opted vessels in a model of neuroblastoma. Proc Natl Acad Sci USA 99:11399-11404, 2002.
60. Hood JD, Cheresh DA: Building a better Trap. Proc Natl Acad Sci U S A 100:8624-8625, 2003.
61. Dupont L, Schwartz J, Koutcher D, et al: Phase I and pharmacokinetic study of VEGFTrap administered subcutaneously (sc) to patients (pts) with advanced solid malignancies (abstract 3009). Proc Am Soc Clin Oncol 23:197, 2004.
62. Kerbel RS: Tumor angiogenesis: Past, present, and the near future. Carcinogenesis 21:505-515, 2000.
63. Carter SK: Clinical strategy for the development of angiogenesis inhibitors. Oncologist 5(suppl 1):51-54, 2000
64. Deplanque G, Harris AL: Anti-angiogenic agents: Clinical trial design and therapies in development. Eur J Cancer 36:1713-1724, 2000.
65. Marzola P, Degrassi A, Calderan L, et al: In vivo assessment of antiangiogenic activity of SU6668 in an experimental colon carcinoma model. Clin Cancer Res 10:739-750, 2004.
66. Jain RK: Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy. Nat Med 7:987-989, 2001.